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We aimed to identify independent predictors of cardiac mortality and hospitalization for heart failure 
(HHF) from a real-world, multi-ethnic Asian registry [the Singapore Myocardial Infarction Registry] 
of st-segment elevation myocardial infarction (steMI) patients treated by primary percutaneous 
coronary intervention. 11,546 eligible STEMI patients between 2008 and 2015 were identified. 
In-hospital, 30-day and 1-year cardiac mortality and 1-year HHF rates were 6.4%, 6.8%, 8.3% and 
5.2%, respectively. From the derivation cohort (70% of patients), age, Killip class and cardiac arrest, 
creatinine, hemoglobin and troponin on admission and left ventricular ejection fraction (LVEF) during 
hospitalization were predictors of in-hospital, 30-day and 1-year cardiac mortality. Previous ischemic 
heart disease (IHD) was a predictor of in-hospital and 30-day cardiac mortality only, whereas diabetes 
was a predictor of 1-year cardiac mortality only. Age, previous IHD and diabetes, Killip class, creatinine, 
hemoglobin and troponin on admission, symptom-to-balloon-time and LVEF were predictors of 1-year 
HHF. The c-statistics were 0.921, 0.901, 0.881, 0.869, respectively. Applying these models to the 
validation cohort (30% of patients) showed good fit and discrimination (c-statistic 0.922, 0.913, 0.903 
and 0.855 respectively; misclassification rate 14.0%, 14.7%, 16.2% and 24.0% respectively). These 
predictors could be incorporated into specific risk scores to stratify reperfused STEMI patients by their 
risk level for targeted intervention.
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Despite prompt reperfusion of ST-segment elevation myocardial infarction (STEMI) by primary percutaneous 
coronary intervention (PPCI), morbidity and mortality remain significant1,2. However, not all STEMI patients 
have the same prognosis. Those in the low-risk category have excellent prognosis3, whereas those with high-risk 
features have significantly worse outcomes with the risk of all-cause mortality reaching up to 35% at 30-day in 
those in the highest risk category4. Therefore early risk-stratification of STEMI patients is important to guide 
in-patient management and follow-up in order to improve clinical outcomes.
There are several risk scores available which can be used to risk-stratify STEMI patients at the time of hospi-
talization, and guide management5. The most extensively investigated, and validated risk scores are the Global 
Registry of Acute Coronary Events (GRACE)6,7, and the Thrombolysis in Myocardial Infarction (TIMI)4 risk 
scores, with the GRACE score performing better than the TIMI risk score in a recent meta-analysis8. The GRACE 
score can be used for all types of acute coronary syndromes (ACS), and can predict in-hospital and 6-month 
mortality. On the other hand, there is a specific TIMI risk score for STEMI4 to predict 30-day mortality. However, 
the derivation and validation cohorts for these risk scores consisted predominantly of non-Asian patients treated 
by thrombolysis.
About 60% of the world population resides in the Asia-Pacific region1 and Asians are known to have a different 
and higher cardiovascular risk profile than the western population9. However, there has been limited research 
conducted in the ACS population in this region so far due to factors such as language and cultural barriers, 
potential ethical issues, and differences in regulatory processes in individual Asian countries10, but efforts are 
under way with the establishment of the Asia-Pacific Real world evIdenCe on Outcome and Treatment of ACS 
(APRICOT) project1.
Singapore is a multi-ethnic country with Chinese (≈74%), Malays (≈13%) and Indians (≈9%) accounting 
for the majority of the population. It has a state-funded, mandatory, acute myocardial infarction (AMI) regis-
try, called the Singapore Myocardial Infarction Registry (SMIR)11, with a dedicated team to collect data from 
all hospitals. We used this unbiased, real-world registry to determine independent variables on admission that 
would predict cardiac mortality during hospitalization, at 30-day and 1-year and 1-year hospitalization for heart 
failure (HHF) in patients presenting with a STEMI and reperfused by PPCI. These variables would subsequently 
be incorporated in risk scores to stratify reperfused STEMI patients by their risk level for targeted intervention 
early during hospitalization.
Results
Study population and baseline characteristics. A total of 11,546 STEMI patients reperfused by PPCI 
from 2008 to 2015 were identified in the SMIR. The overall cardiac mortality rate during hospitalization was 6.4% 
(741/11,546) and was 6.8% (780/11,546) at 30 days and 8.3% (956/11,546) at 1 year. Data on 1-year HHF was 
available from 2008 to 2013 only (n = 7,446). The 1-year HHF rate was 5.4% (399/7,446).
There were 8,082 reperfused STEMI patients in the derivation cohort. The median age was 57.6 (50.7–66.1) 
years old and 85.2% were male. The majority were Chinese (61.4%), followed by Malays (20.1%) and Indians 
(16.8%). Around a third of the cohort had a history of diabetes (28.1%) and half had a history of hypertension 
(52.2%), dyslipidemia (46.0%) and were current smokers (49.1%). 4.0% suffered a cardiac arrest in the ambulance 
or on admission to the emergency department and 8.7% were in cardiogenic shock at presentation. Half of the 
patients presented with an anterior STEMI (49.8%), and half had an abnormal initial troponin T or I (48.7%). The 
median symptom-to-balloon (S2B) time was 183 (120–310) minutes and the door-to-balloon (D2B) time was 65 
(50–88) minutes.
There were 3,464 reperfused STEMI patients in the validation cohort. There was no significant difference in 
baseline characteristics between the derivation cohort and the validation cohort as summarized in Table 1 except 
for body mass index.
Predictors of in-hospital, 30-day and 1-year cardiac mortality. Variables included in the univariable 
logistic regression are summarized in the Table 2. Variables included in the multivariable logistic regression are 
summarized in Table 3. Age, Killip class, cardiac arrest, creatinine, hemoglobin and troponin on admission and 
left ventricular ejection fraction (LVEF) during hospitalization were predictors of cardiac mortality at all 3 time 
points (in-hospital, 30-day and 1 year). Previous ischemic heart disease (IHD) - defined as a history of previous 
myocardial infarction, PCI or coronary artery bypass graft surgery - was a predictor of in-hospital and 30-day 
cardiac mortality only, whereas diabetes was a predictor of 1-year cardiac mortality only.
Calibration of the predictions from these models was assessed by comparing the average predictions to the 
actual cardiac mortality across deciles and was found to be excellent as shown in Fig. 1. Internal validation 
showed good fit of the models with a c-statistic of 0.921 (95%CI 0.910–0.932) for in-hospital cardiac mortality, 
0.901 (95%CI 0.887–0.915) for 30-day cardiac mortality and 0.881 (95%CI 0.867–0.896) for 1-year cardiac mor-
tality with bootstrapping techniques.
External validation was performed in the validation cohort of 3,464 patients. The model performed very well 
as shown in Fig. 2 with a c-statistic of 0.922 (95%CI 0.902–0.942) for in-hospital cardiac mortality, 0.913 (95%CI 
0.891–0.935) for 30-day cardiac mortality and 0.903 (95%CI 0.882–0.923) for 1-year cardiac mortality. The mis-
classification rate for in-hospital, 30-day and 1-year cardiac mortality was 14.0%, 14.7% and 16.2% respectively.
Predictors of 1-year hospitalization for heart failure. The derivation cohort consisted of 5,395 reper-
fused STEMI patients and the validation cohort consisted of 2,280 reperfused STEMI patients.
Age, previous IHD and diabetes, Killip class, creatinine, hemoglobin and troponin on admission, S2B time 
and LVEF were predictors of 1-year HHF (Table 4).
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Derivation cohort 
(n = 8082)
Validation cohort 
(n = 3464) P
Age in years, median (IQR) 57.6 (50.7–66.1) 57.9 (50.9–66.0) 0.536
Age group, n (%)
0.597
<40 331 (4.1) 148 (4.3)
40–59 4369 (54.1) 1833 (52.9)
60–69 1952 (24.2) 857 (24.7)
70–79 1016 (12.6) 461 (13.3)
> = 80 414 (5.1) 165 (4.8)
Gender, n (%)
0.361Male 6885 (85.2) 2928 (84.5)
Female 1197 (14.8) 536 (15.5)
Ethnicity, n (%)
0.072
Chinese 4960 (61.4) 2167 (62.6)
Malay 1622 (20.1) 722 (20.8)
Indian 1360 (16.8) 515 (14.9)
Others 140 (1.7) 60 (1.7)
History of diabetes, n (%) 2273 (28.1) 980 (28.3) 0.853
History of hypertension, n (%) 4220 (52.2) 1796 (51.9) 0.72
History of dyslipidemia, n (%) 3712 (46.0) 1588 (45.9) 0.902
History of IHD, n (%) 1212 (15.0) 532 (15.4) 0.63
Current smoker, n (%) 3926 (49.1) 1718 (50.1) 0.34
BMI in kg/m2, median (IQR) 24.6 (22.4–27.3) 24.4 (22.2–27.1) 0.034
BMI group, n (%)
0.041< = 23 2255 (30.9) 1032 (32.9)
>23 5041 (69.1) 2101 (67.1)
Killip class on admission, n (%)
0.297
I 6703 (83.0) 2849 (82.3)
II 385 (4.8) 158 (4.6)
III 288 (3.6) 148 (4.3)
IV 705 (8.7) 309 (8.9)
Cardiac arrest in ambulance/on admission, n (%) 319 (4.0) 155 (4.5) 0.19
Anterior STEMI on admission, n (%) 4022 (49.8) 1736 (50.1) 0.73
Creatinine on admission in µmol/L, median (IQR) 90 (76–109) 90 (77–109) 0.718
Creatinine group, n (%)
0.615
<70 1177 (14.6) 519 (15.1)
70–105 4622 (57.3) 1944 (56.5)
106–140 1501 (18.6) 675 (19.6)
141–176 364 (4.5) 152 (4.4)
177–353 269 (3.3) 100 (2.9)
> = 354 135 (1.7) 54 (1.6)
Hemoglobin on admission in g/dL, median (IQR) 14.6 (13.5–15.7) 14.7 (13.4–15.7) 0.58
Hemoglobin group, n (%)
0.633
<10 185 (2.3) 87 (2.5)
10–11 547 (6.8) 258 (7.5)
12–13 2031 (25.2) 863 (25.1)
14–16 3693 (45.8) 1563 (45.4)
> = 17 1609 (20.0) 674 (19.6)
Elevated first troponin T/I on admission, n (%) 3938 (48.7) 1649 (47.6) 0.269
Blood sugar within 72 h from STEMI onset in mmol/L, median (IQR) 8.5 (6.7–12.2) 8.4 (6.7–12.1) 0.287
Total cholesterol within 72 h from STEMI onset in mmol/L, median (IQR) 5.1 (4.3–6.0) 5.1 (4.3–6.0) 0.514
HDL cholesterol within 72 h from STEMI onset in mmol/L, median (IQR) 1.0 (0.9–1.2) 1.0 (0.9–1.2) 0.431
LDL cholesterol within 72 h from STEMI onset in mmol/L, median (IQR) 3.4 (2.6–4.1) 3.3 (2.6–4.1) 0.264
Triglyceride within 72 h from STEMI onset in mmol/L, median (IQR) 1.4 (1.0–2.0) 1.4 (1.0–2.0) 0.98
HbA1c on admission in %, median (IQR) 6.1 (5.7–7.6) 6.1 (5.7–7.7) 0.97
S2B time in minutes, median (IQR) 183 (120–310) 180 (119–298) 0.118
Continued
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Calibration of the predictions from this model was assessed by comparing the average predictions to the actual 
HHF across deciles and was found to be excellent (Fig. 1). Internal validation showed good fit of the models with 
a c-statistic of 0.868 (95%CI 0.848–0.888) for 1-year HHF.
External validation showed that the model performed very well with a c-statistic of 0.855 (95%CI 0.823–
0.888), with misclassification rate of 24.0% (Fig. 2).
Figure 3 shows the variables that made up each risk score and the score associated with each variable. These 
risk scores could potentially be incorporated into a calculator to facilitate usage in the clinical setting.
Discussion
The strength of the SMIR is that it is a mandatory registry and as such, all STEMI patients treated by PPCI 
between 2008 and 2013 were captured in a cohort of multi-ethnic Asian STEMI patients, comprising predom-
inantly of Chinese, Malays and Indians, reperfused by PPCI in the current era. Unlikely other risk scores pre-
dicting all-cause mortality, we have identified independent predictors of cardiac mortality. All these variables 
are available either at the time of admission or within the first few hours following admission and can be used to 
predict in-hospital, 30-day and 1-year cardiac mortality and 1-year HHF early during hospitalization.
The potential immediate utility of these predictors is to identify those low risk patients who could be dis-
charged early (e.g. after 48–72 hours). Secondly, it could potentially be used to identify those at high risk and 
who would benefit from more aggressive up-titration of their prognostic medications (beta-blockers, angiotensin 
converting enzyme inhibitors, aldosterone antagonists etc.) and more frequent follow-ups. Last but not least, this 
score could also be used when counseling patients prior to discharge regarding their prognosis.
The initial derivation cohort of the GRACE registry consisted of 13,708 patients recruited between 1999 
and 2001 and only a third presented with a STEMI and only 15.2% received reperfusion therapy6. Furthermore, 
they only reported in-hospital and 6 months mortality. Although the recruitment was done in 14 countries, 
none were from Asia. However, the GRACE2 was subsequently expanded to more countries, including hos-
pitals in Asia12. The risk profiles and prognosis for STEMI and NSTEMI are different13,14 and therefore devel-
oping risk scores specific for STEMI and NSTEMI may provide a more accurate prediction of their prognosis. 
The TIMI risk score has a dedicated score for STEMI4. The derivation cohort in the TIMI STEMI risk score 
was recruited from >800 hospitals4. However, it was not clear how many patients were Asians. Although 
15,078 patients were enrolled between 1997 and 1998, they only included patients presenting within 6 hours of 
symptoms onset and only reported 30-day mortality4. The derivation cohort of the Controlled Abciximab and 
Device Investigation to Lower Late Angioplasty Complications (CADILLAC) score15 included 2,082 STEMI 
patients recruited from 1997 to 1999 into a randomized controlled trial. Patients presenting within 12 hours 
of symptoms onset were included and those in cardiogenic shock at presentation were excluded and there-
fore patients in this cohort were not representative of the real world population. The Primary Angioplasty 
in Myocardial Infarction II (PAMI-II) criteria16 (for 6-month mortality) and Zwolle PPCI index17 (30-day 
mortality) can also be used to identify low risk patients for early discharge2 but they were both derived from 
non-Asian cohorts with patients recruited in the 1990s, with the former comprising of 3,252 patients from 
Derivation cohort 
(n = 8082)
Validation cohort 
(n = 3464) P
S2B time group, n (%)
0.205< = 180 3738 (49.2) 1654 (50.5)
>180 3865 (50.8) 1622 (49.5)
D2B in minutes, median (IQR) 65 (50–88) 64 (49–87) 0.435
Lowest LVEF during hospitalization in %, median (IQR) 45 (35–55) 45 (35–55) 0.874
LVEF group, n (%)
0.372
<40 2244 (29.5) 963 (30.0)
40–50 3153 (41.5) 1286 (40.1)
>50 2201 (29.0) 960 (29.9)
Aspirin given during hospitalization, n (%) 7710 (95.4) 3278 (94.6) 0.078
Beta blocker given during hospitalization, n (%) 6793 (84.1) 2854 (82.4) 0.027
Lipid lowering therapy/statin given during hospitalization, n (%) 7710 (95.4) 3282 (94.8) 0.134
ACEI/ARB given during hospitalization, n (%) 5932 (73.4) 2537 (73.2) 0.86
Other anti-platelet given during hospitalization, n (%) 7800 (96.5) 3327 (96.1) 0.22
Aspirin given at discharge among those discharged alive, n (%) 7323 (97.1) 3102 (97.0) 0.935
Beta blocker given at discharge among those discharged alive, n (%) 6592 (87.4) 2766 (86.5) 0.229
Lipid lowering therapy/statin given at discharge among those discharged alive, n (%) 7377 (97.8) 3141 (98.3) 0.115
ACEI/ARB given at discharge among those discharged alive, n (%) 5568 (73.8) 2390 (74.8) 0.299
Other anti-platelet given at discharge among those discharged alive, n (%) 7405 (98.1) 3150 (98.5) 0.163
Table 1. Baseline characteristics in the derivation and validation cohort. IQR: interquartile range; IHD: 
ischemic heart disease; BMI: body mass index; STEMI: ST-segment elevation myocardial infarction; S2B: 
symptom-to-balloon; D2B: door-to-balloon; LVEF: left ventricular ejection fraction; ACE: angiotensin 
converting enzyme inhibitor; ARB: angiotensin receptor blocker.
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In-hospital cardiac mortality 30-day cardiac mortality 1-year cardiac mortality
Odds Ratio (95%CI) P Odds Ratio (95%CI) P Odds Ratio (95%CI) P
Age (years)
<0.001 <0.001 <0.001
<40 1.00 (reference) 1.00 (reference) 1.00 (reference)
40–59 2.95 (1.08–8.00) 2.64 (1.08–6.47) 3.21 (1.31–7.85)
60–69 5.21 (1.91–14.22) 4.27 (1.73–10.53) 5.86 (2.39–14.38)
70–79 12.53 (4.60–34.14) 10.59 (4.30–26.08) 14.04 (5.72–34.45)
> = 80 21.75 (7.89–59.95) 18.11 (7.26–45.15) 23.59 (9.50–58.60)
Gender
<0.001 <0.001 <0.001Male 1.00 (reference) 1.00 (reference) 1.00 (reference)
Female 2.52 (2.05–3.09) 2.42 (1.98–2.96) 2.48 (2.07–2.98)
Ethnicity
0.105 0.105 0.072
Chinese 1.00 (reference) 1.00 (reference) 1.00 (reference)
Malay 1.01 (0.80–1.27) 1.05 (0.84–1.31) 1.09 (0.90–1.33)
Indian 0.77 (0.59–1.01) 0.77 (0.59–1.01) 0.77 (0.61–0.98)
Others 1.52 (0.85–2.73) 1.44 (0.80–2.57) 1.23 (0.70–2.15)
History of diabetes
<0.001 <0.001 <0.001No 1.00 (reference) 1.00 (reference) 1.00 (reference)
Yes 2.10 (1.74–2.52) 1.98 (1.66–2.37) 2.18 (1.86–2.57)
History of hypertension
<0.001 <0.001 <0.001No 1.00 (reference) 1.00 (reference) 1.00 (reference)
Yes 1.75 (1.45–2.12) 1.75 (1.45–2.10) 2.01 (1.70–2.38)
History of dyslipidemia
0.168 0.316 0.002No 1.00 (reference) 1.00 (reference) 1.00 (reference)
Yes 1.14 (0.95–1.36) 1.09 (0.92–1.31) 1.28 (1.09–1.50)
History of IHD
0.014 0.011 <0.001No 1.00 (reference) 1.00 (reference) 1.00 (reference)
Yes 1.34 (1.06–1.70) 1.34 (1.07–1.69) 1.75 (1.44–2.12)
Current smoker
<0.001 <0.001 <0.001No 1.00 (reference) 1.00 (reference) 1.00 (reference)
Yes 0.53 (0.43–0.64) 0.61 (0.50–0.74) 0.59 (0.49–0.70)
BMI (kg/m2)
0.057 0.026 0.016< = 23 1.00 (reference) 1.00 (reference) 1.00 (reference)
>23 0.80 (0.63–1.01) 0.78 (0.62–0.97) 0.79 (0.65–0.96)
Killip class on admission
<0.001 <0.001 <0.001
I 1.00 (reference) 1.00 (reference) 1.00 (reference)
II 2.12 (1.36–3.31) 2.33 (1.55–3.51) 2.27 (1.59–3.25)
III 7.88 (5.68–10.92) 7.66 (5.59–10.52) 7.52 (5.64–10.02)
IV 15.24 (12.31–18.87) 13.58 (11.03–16.73) 11.58 (9.55–14.05)
Cardiac arrest in ambulance/on 
admission
<0.001 <0.001 <0.001No 1.00 (reference) 1.00 (reference) 1.00 (reference)
Yes 12.87 (10.05–16.50) 11.07 (8.65–14.18) 9.37 (7.37–11.91)
Anterior STEMI
0.001 <0.001 <0.001No 1.00 (reference) 1.00 (reference) 1.00 (reference)
Yes 1.37 (1.14–1.65) 1.44 (1.21–1.72) 1.37 (1.16–1.60)
Creatinine on admission (µmol/L)
<0.001 <0.001 <0.001
<70 1.00 (reference) 1.00 (reference) 1.00 (reference)
70–105 1.26 (0.83–1.92) 1.23 (0.83–1.82) 1.11 (0.80–1.55)
106–140 4.83 (3.19–7.33) 4.57 (3.09–6.75) 3.82 (2.74–5.33)
141–176 10.87 (6.87–17.20) 9.59 (6.19–14.87) 8.02 (5.47–11.76)
177–353 17.71 (11.15–28.14) 15.10 (9.69–23.52) 13.08 (8.85–19.31)
> = 354 9.68 (5.43–17.26) 7.99 (4.53–14.10) 9.50 (5.87–15.37)
Hemoglobin on admission (g/dL)
<0.001 <0.001 <0.001
<10 1.00 (reference) 1.00 (reference) 1.00 (reference)
11–11 0.86 (0.57–1.31) 0.84 (0.55–1.27) 0.78 (0.53–1.15)
12–13 0.36 (0.24–0.53) 0.34 (0.23–0.50) 0.32 (0.23–0.46)
14–16 0.16 (0.11–0.23) 0.16 (0.11–0.23) 0.14 (0.10–0.21)
> = 17 0.14 (0.09–0.21) 0.16 (0.11–0.25) 0.14 (0.10–0.21)
Continued
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an RCT and the latter including 1,791 patients from a registry for their derivation cohorts. The Korean Acute 
Myocardial Infarction Registry (KAMIR)18 recently reported a risk score for Asians, derived from a cohort of 
14,885 patients but it was not clear how the risk score was derived18. There was only one Asian ethnic group 
represented and they combined both STEMI and NSTEMI patients who either underwent invasive reperfusion 
strategy or were medically managed. They only reported 1-year mortality and they showed that the KAMIR 
score performed better than the GRACE score both in the NSTEMI and STEMI, highlighting the need for a risk 
score that is specific to the local population18. Most recently, the Acute Coronary Treatment and Intervention 
Outcomes Network (ACTION) risk score used to predict in-hospital mortality in ACS was reported19. They 
included a total of 243,440 patients and unlike the SMIR, entry in the former registry was voluntary. Moreover, 
they consisted predominantly of Caucasians and African Americans and they combined both STEMI and 
NSTEMI in the model. Although they showed that STEMI had worse outcomes in their model, it is likely that 
the other components of their score would have carried different weight for STEMI and NSTEMI if they were 
analyzed separately. The SMIR STEMI risk score is novel as it included all consecutive STEMI patients treated 
by PPCI as part of a compulsory nationwide registry and it can predict in-hospital, 30-day and 1-year cardiac 
mortality in a specific group of patients (STEMI patients reperfused by PPCI) in a multi-ethnic Asian cohort. 
Table 5 summarizes the prognostic variables included in the SMIR STEMI risk score in comparison to variables 
in the GRACE, TIMI STEMI, CADILLAC, PAMI-II, Zwolle, KAMIR and ACTION scores. All variables were 
present in at least one of the other risk scores in one form or another.
Limitations. We did not perform a direct comparison of the performance of the SMIR STEMI risk score 
against the GRACE score, which is currently the most popular, due to data on heart rate and blood pressure 
not being collected on admission. Less than 3% of the reperfused STEMI patients underwent thrombolysis 
from 2008 to 2015 and were not included in this analysis. Therefore whether the SMIR STEMI risk score 
would perform well in those Asian countries where thrombolysis is still widely used for STEMI1 remains to 
be investigated. Angiographic data were not available and were not included in the score. Furthermore pro-
cedural data (culprit only PCI or multi-vessel PCI) were also not available. However, a previous study20 have 
shown that the angiographic variables provided only a minor improvement in the c-statistic of a risk score 
to predict in-hospital mortality in patients undergoing PCI procedures. We did not include events occurring 
during hospitalization that could have improved the risk prediction for 30-day and 1-year cardiac mortality, 
as we wanted to keep the model simple, for easy adoption in the clinical setting. Only the admission troponin 
was included in the model as the discharge troponin was performed at variable time point and the assays 
used were not standardized among the various hospitals. Therefore it was not possible to provide reliable data 
regarding how the latter correlated with outcomes. The follow-up period was 1 year only and a longer period of 
follow-up would have provided further valuable information on the longer-term outcomes of these patients. As 
the risk score for HHF excluded patients who died due to non-HF causes within 1 year from STEMI discharge 
and without HF admission, the competing risk from non-HF death may have biased the HHF risk score and 
undermined its usefulness. Last but not least, we used the ICD codes to identify HHF endpoints and the latter 
has been shown to fail to capture all HHF events in western health care system21. Whether this holds true in 
the Singapore health care system with a dedicated team to collect all outcomes in this compulsory nationwide 
registry remains to be seen.
Conclusion
We used a real-world, national AMI registry to identify independent predictors of in-hospital, 30-day and 1-year 
cardiac mortality and 1-year HHF in a multi-ethnic Asian STEMI patients reperfused by PPCI. We have provided 
the variables and their associated scores that could be incorporated into a risk score to risk-stratify patients and 
guide duration of hospital stay, short and medium term management and follow-up, to improve outcomes in 
these patients.
In-hospital cardiac mortality 30-day cardiac mortality 1-year cardiac mortality
Odds Ratio (95%CI) P Odds Ratio (95%CI) P Odds Ratio (95%CI) P
Elevated first troponin T/I on admission
<0.001 <0.001 <0.001No 1.00 (reference) 1.00 (reference) 1.00 (reference)
Yes 2.08 (1.72–2.52) 2.11 (1.75–2.54) 2.15 (1.82–2.54)
S2B (minutes)
0.534 0.287 0.178< = 180 1.00 (reference) 1.00 (reference) 1.00 (reference)
>180 1.06 (0.88–1.29) 1.11 (0.92–1.34) 1.12 (0.95–1.33)
Lowest LVEF during hospitalization (%)
<0.001 <0.001 <0.001
<40 1.00 (reference) 1.00 (reference) 1.00 (reference)
40–50 0.12 (0.09–0.17) 0.14 (0.11–0.19) 0.15 (0.12–0.19)
>50 0.10 (0.07–0.15) 0.10 (0.06–0.14) 0.12 (0.09–0.16)
Table 2. Univariable regression model for prediction of cardiac mortality based on the derivation cohort. 
CI: confidence interval; IHD: ischemic heart disease; BMI: body mass index; STEMI: ST-segment elevation 
myocardial infarction; S2B: symptom-to-balloon; LVEF: left ventricular ejection fraction.
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In-hospital cardiac mortality 30-day cardiac mortality 1-year cardiac mortality
Odds Ratio (95%CI) P Odds Ratio (95%CI) P Odds Ratio (95%CI) P
Age (years)
<0.001 <0.001 <0.001
<40 1.00 (reference) 1.00 (reference) 1.00 (reference)
40–59 4.26 (0.58–31.41) 2.91 (0.70–12.16) 3.84 (0.93–15.93)
60–69 5.92 (0.80–44.08) 3.42 (0.81–14.48) 5.55 (1.33–23.20)
70–79 9.46 (1.26–70.99) 5.94 (1.39–25.39) 9.57 (2.27–40.33)
> = 80 18.48 (2.44–140.17) 10.71 (2.47–46.46) 17.26 (4.04–73.63)
Gender
Not significant Not significant Not significantMale
Female
History of diabetes
Not significant Not significant 0.014No 1.00 (reference)
Yes 1.33 (1.06–1.67)
History of hypertension
Not significant Not significant Not significantNo
Yes
History of dyslipidemia
NA NA Not significantNo
Yes
History of IHD
0.001 0.006 Not significantNo 1.00 (reference) 1.00 (reference)
Yes 0.55 (0.38–0.80) 0.62 (0.44–0.87)
Current smoker
Not significant Not significant Not significantNo
Yes
BMI (kg/m2)
< = 23
>23
Not significant Not significant Not significant
Killip class on admission
<0.001 <0.001 <0.001
I 1.00 (reference) 1.00 (reference) 1.00 (reference)
II 1.07 (0.59–1.93) 1.20 (0.71–2.03) 1.13 (0.73–1.76)
III 2.77 (1.79–4.31) 2.70 (1.79–4.09) 2.42 (1.68–3.48)
IV 4.24 (3.11–5.77) 3.75 (2.79–5.05) 3.27 (2.50–4.27)
Cardiac arrest in ambulance/on 
admission
<0.001 <0.001 <0.001No 1.00 (reference) 1.00 (reference) 1.00 (reference)
Yes 6.61 (4.52–9.65) 5.09 (3.52–7.37) 4.55 (3.20–6.46)
Anterior STEMI
Not significant Not significant Not significantNo
Yes
Creatinine on admission (µmol/L)
<0.001 <0.001 <0.001
<70 1.00 (reference) 1.00 (reference) 1.00 (reference)
70–105 1.26 (0.73–2.16) 1.19 (0.73–1.95) 1.11 (0.75–1.64)
106–140 2.36 (1.36–4.09) 2.29 (1.39–3.77) 1.92 (1.28–2.89)
141–176 3.74 (2.01–6.96) 3.16 (1.77–5.62) 2.55 (1.57–4.13)
177–353 5.04 (2.67–9.52) 4.08 (2.26–7.38) 3.25 (1.97–5.38)
> = 354 4.37 (1.97–9.70) 2.94 (1.36–6.38) 3.79 (2.05–6.99)
Hemoglobin on admission (g/dL)
<0.001 0.001 <0.001
<10 1.00 (reference) 1.00 (reference) 1.00 (reference)
10–11 1.94 (1.05–3.59) 1.57 (0.88–2.80) 1.47 (0.87–2.46)
12–13 1.13 (0.62–2.06) 0.87 (0.50–1.53) 0.96 (0.59–1.59)
14–16 0.73 (0.39–1.35) 0.59 (0.33–1.05) 0.67 (0.40–1.12)
> = 17 0.77 (0.38–1.56) 0.81 (0.43–1.54) 0.89 (0.50–1.57)
Elevated first troponin T/I on 
admission
<0.001 <0.001 <0.001No 1.00 (reference) 1.00 (reference) 1.00 (reference)
Yes 1.69 (1.27–2.25) 1.76 (1.35–2.30) 1.68 (1.34–2.12)
Continued
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Methods
Population. This was a retrospective study on data collected prospectively between 2008 and 2015 by the 
National Registry of Diseases Office in SMIR. Data collection on all AMI cases from all public and private hospi-
tals is mandated and funded by the state and yearly reports are generated for the Ministry of Health11,22,23. Ethics 
approval was obtained from the SingHealth Centralized Institutional Review Board and the requirement for 
patient consent was waived. The study was conducted according to the Declaration of Helsinki.
Inclusion and Exclusion criteria. The main inclusion criteria were patients presenting to hospital with a 
STEMI within 12 hours of symptoms onset and were reperfused by PPCI. Patients with a STEMI but not reper-
fused by PPCI or those with a LBBB were excluded as shown in the flow chart in Fig. 4.
In-hospital cardiac mortality 30-day cardiac mortality 1-year cardiac mortality
Odds Ratio (95%CI) P Odds Ratio (95%CI) P Odds Ratio (95%CI) P
S2B (minutes)
< = 180
>180
Not significant Not significant Not significant
Lowest LVEF during 
hospitalization (%)
<0.001 <0.001 <0.001<40 1.00 (reference) 1.00 (reference) 1.00 (reference)
40–50 0.21 (0.15–0.30) 0.24 (0.18–0.33) 0.25 (0.19–0.32)
>50 0.25 (0.16–0.38) 0.22 (0.14–0.34) 0.27 (0.19–0.37)
Table 3. Multivariable regression model for prediction of cardiac mortality based on the derivation cohort. 
CI: confidence interval; IHD: ischemic heart disease; BMI: body mass index; STEMI: ST-segment elevation 
myocardial infarction; S2B: symptom-to-balloon; LVEF: left ventricular ejection fraction; NA: not applicable.
Figure 1. Internal validation of the models in the derivation cohort. There was good calibration of the models 
for in-hospital, 30-day and 1-year cardiac death and 1-year HHF with c-statistic of 0.921, 0.901, 0.881 and 0.868 
respectively.
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Clinical outcomes of interest. The main outcomes of interest were in-hospital cardiac mortality, 30-day 
cardiac mortality, 1-year cardiac mortality and 1-year HHF. Specifically for HHF, the data was available for 
2008 to 2013 only. Patients who died during hospitalization for STEMI were excluded for this outcome. Among 
patients discharged alive, patients who died due to HF within 1 year from STEMI discharge but without HF 
admission were included. However, patients who died due to non-HF causes within 1 year from STEMI discharge 
and without HF admission were excluded.
Data collection. Registry coordinators confirmed all diagnosis of STEMI from physical and electronic med-
ical records and data on patients’ demographics, comorbidities, location of STEMI on ECG, initial blood results 
such as hemoglobin, creatinine and troponin T or I were extracted. Details on Killip class and cardiac arrest in the 
ambulance or on admission (prior to transfer to the cardiac catheterization laboratory) and S2B/ D2B times were 
also recorded. The International Classification of Diseases 9th Revision (ICD-9 Clinical Modification) code 410 
was used to identify STEMI cases diagnosed from 2008 to 2011, whereas ICD-10 codes I21 and I22 were used for 
STEMI cases diagnosed from 2012 to 2015. Data on admission heart rate and blood pressure were not available 
in this registry.
STEMI was defined by a typical chest pain of 20 minutes and significant ST-segment elevation (0.1 or 0.2 mV 
on two adjacent limb or precordial leads), and with a corresponding rise in cardiac biomarkers. Troponin T or 
I performed on admission was defined as abnormal if they were greater than the 99th percentile of the reference 
range from each hospital laboratory.
Cardiac mortality was identified as death occurring from a cardiac cause and defined by the ICD codes 
(ICD-9: 391–398, 402, 410–429; ICD-10: I00-I52 except I26). The time of death was extracted from death certif-
icates obtained from the Registry of Births and Deaths. As the reporting of death is mandatory for all Singapore 
Figure 2. External validation of the models in the validation cohort. There was good discrimination of the 
models for in-hospital, 30-day and 1-year cardiac death and 1-year HHF with c-statistic of 0.922, 0.913, 0.903 
and 0.855 respectively.
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Heart failure hospitalization Heart failure hospitalization
Odds Ratio (95%CI) P Odds Ratio (95%CI) P
Age (years)
<0.001 0.025
<40 1.00 (reference) 1.00 (reference)
40–59 1.83 (0.74–4.54) 1.93 (0.67–5.58)
60–69 3.55 (1.42–8.84) 2.49 (0.84–7.33)
70–79 4.67 (1.84–11.82) 2.46 (0.80–7.53)
> = 80 8.40 (3.18–22.15) 4.38 (1.37–14.04)
Gender
<0.001 Not significantMale 1.00 (reference)
Female 2.28 (1.72–3.02)
Ethnicity
0.095 NA
Chinese 1.00 (reference)
Malay 1.40 (1.05–1.88)
Indian 1.24 (0.90–1.70)
Others 0.70 (0.22–2.24)
History of diabetes
<0.001 <0.001No 1.00 (reference) 1.00 (reference)
Yes 3.33 (2.62–4.24) 2.07 (1.54–2.77)
History of hypertension
<0.001 Not significantNo 1.00 (reference)
Yes 2.73 (2.08–3.57)
History of dyslipidemia
<0.001 Not significantNo 1.00 (reference)
Yes 2.02 (1.58–2.59)
History of IHD
<0.001 <0.001No 1.00 (reference) 1.00 (reference)
Yes 3.14 (2.42–4.08) 2.14 (1.56–2.94)
Current smoker
0.008 Not significantNo 1.00 (reference)
Yes 0.72 (0.57–0.92)
BMI (kg/m2)
0.32 NA< = 23 1.00 (reference)
>23 0.88 (0.67–1.14)
Killip class on admission
<0.001 <0.001
I 1.00 (reference) 1.00 (reference)
II 4.70 (3.23–6.84) 2.85 (1.84–4.41)
III 5.66 (3.57–8.96) 1.95 (1.10–3.47)
IV 5.20 (3.72–7.27) 2.72 (1.81–4.08)
Cardiac arrest in ambulance/on admission
0.344 NANo 1.00 (reference)
Yes 1.39 (0.70–2.78)
Anterior STEMI
<0.001 Not significantNo 1.00 (reference)
Yes 1.83 (1.43–2.34)
Creatinine on admission (µmol/L)
<0.001 <0.001
<70 1.00 (reference) 1.00 (reference)
70–105 0.89 (0.60–1.30) 1.15 (0.73–1.82)
106–140 1.75 (1.14–2.67) 1.63 (0.98–2.73)
141–176 3.97 (2.35–6.71) 3.20 (1.71–6.02)
177–353 6.46 (3.79–11.02) 2.50 (1.24–5.03)
> = 354 0.37 (0.05–2.74) 0.15 (0.02–1.31)
Hemoglobin on admission (g/dL)
<0.001 0.003
<10 1.00 (reference) 1.00 (reference)
10–11 1.25 (0.60–2.60) 1.57 (0.57–4.28)
12–13 0.52 (0.26–1.04) 0.91 (0.34–2.39)
14–16 0.28 (0.14–0.56) 0.62 (0.23–1.63)
> = 17 0.31 (0.15–0.64) 0.93 (0.34–2.56)
Continued
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residents and the vital statuses of study population (patients with STEMI in January 2008 to December 2015) 
were matched till 30 June 2017, a date that is beyond one year from the last STEMI case included in this study, no 
patient was lost to follow-up for all mortality outcomes.
Figure 3. Nomograms to predict cardiac mortality and 1-year HHF for individual patients.
Heart failure hospitalization Heart failure hospitalization
Odds Ratio (95%CI) P Odds Ratio (95%CI) P
Elevated first troponin T/I on admission
<0.001 0.049No 1.00 (reference) 1.00 (reference)
Yes 2.26 (1.77–2.90) 1.35 (1.00–1.81)
S2B (minutes)
<0.001 0.003< = 1800 1.00 (reference) 1.00 (reference)
>18 1.70 (1.31–2.20) 1.57 (1.16–2.12)
Lowest LVEF during hospitalization (%)
<0.001 <0.001
<40 1.00 (reference) 1.00 (reference)
40–50 0.17 (0.13–0.23) 0.25 (0.18–0.34)
>50 0.03 (0.02–0.06) 0.04 (0.02–0.10)
Table 4. Univariable and multivariable regression model for prediction of heart failure hospitalization based 
on the derivation cohort. CI: confidence interval; IHD: ischemic heart disease; BMI: body mass index; STEMI: 
ST-segment elevation myocardial infarction; S2B: symptom-to-balloon; LVEF: left ventricular ejection fraction; 
NA: not applicable
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HHF was identified using ICD codes for heart failure admission (ICD-9: 412, 414.10, 414.19, 414.8, 428, 
428.20, 428.21, 428.22, 428.23, 428.30, 428.31, 428.32, 428.33, 428.40, 428.41, 428.42, 428.43, 428.0, 428.9; ICD-
10: I25.2, I25.3, I25.5, I50.1, I50.20, I50.21, I50.22, I50.23, I50.30, I50.31, I50.32, I50.33, I50.40, I50.41, I50.42, 
I50.43, I50.9). No patient was lost to follow-up for HHF as all admitted patients will have a discharge diagnosis. 
However, as the admission data was available till 31 December 2014, 1-year HHF could be matched for patients 
with STEMI in 2008 to 2013 only.
Statistical analysis. Continuous variables were expressed as medians with interquartile ranges and categor-
ical variables were expressed as percentages. All analysis was performed using StataCorp. 2013. Stata Statistical 
Figure 4. Flow chart of STEMI patients from the SMIR included in this study.
Outcome
SMIR GRACE12
TIMI-
STEMI4 CADILLAC15 PAMI-II16 Zwolle17 KAMIR18 ACTION19
In-hospital, 
30-day and 1 
year cardiac 
mortality and 
1-year HHF
6-month 
all-cause 
mortality
1-year 
all-cause 
mortality
1-year 
all-cause 
mortality
6-month 
all-cause 
mortality
30-day 
all-cause 
mortality
1-year AMI 
mortality
In-hospital 
all-cause 
mortality
c-statistic 0.88–0.92 0.82 0.65 0.83 0.78 0.91 0.83 0.88
Age Yes Yes Yes Yes Yes Yes Yes Yes
History of 
diabetes Yes Yes Yes
Yes 
(admission 
glucose)
History of 
hypertension Not significant Yes
History of IHD Yes Yes (angina)
BMI/ weight Not significant Yes (weight)
Killip class Yes Yes Yes Yes Yes Yes Yes Yes
Cardiac arrest Yes Yes Yes
Anterior STEMI Not significant
Yes (ST-
segment 
deviation)
Yes (Anterior 
or LBBB)
Yes 
(Anterior 
or LBBB)
Yes
Creatinine Yes Yes Yes (eGFR <60 ml/min) Yes Yes (CrCl)
Hemoglobin Yes Yes (Anemia)
Troponin T/I Yes Yes Yes
Ischemic time Yes (>3 hours) Yes (>4 hours)
Yes 
(>4 hours)
LVEF during 
hospitalization
Yes (baseline 
LVEF <40%)
Yes (baseline 
LVEF <40%)
Yes 
(baseline 
LVEF 
<40%)
Heart rate Not available Yes Yes Yes Yes
Blood pressure Not available Yes Yes Yes
3-vessel disease Not available Yes Yes
Post PPCI TIMI 
flow Not available Yes Yes
Table 5. Established risk score from GRACE, TIMI STEMI, CADILLAC, PAMI, Zwolle, KAMIR and ACTION. 
HHF: hospitalization for heart failure; STEMI: ST-segment elevation myocardial infarction; BMI: body mass 
index; IHD: ischemic heart disease; LVEF: left ventricular ejection fraction; PPCI: primary percutaneous 
coronary intervention; TIMI: thrombolysis in myocardial infarction.
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Software: Release 13 (College Station, TX: StataCorp LP). The statistical methodology was similar to that used 
for the GRACE score derivation6. Random selection was performed to divide the cohort into two groups with 
70% of the cohort included in the derivation cohort and 30% in the validation cohort. Variables that were prog-
nostic from the GRACE, TIMI STEMI and CADILLAC15 risk scores and that were available from the SMIR were 
included in the univariable logistic regression. Other potentially prognostic variables such as cardiovascular risk 
variables, ethnicity, gender, S2B and D2B were also included in the univariable logistic regression model. Odd 
ratios with 95% confidence interval (95%CI) were used to assess the relationship between the included variables 
and cardiac mortality during hospitalization, within 30 days and within 1 year and 1-year HHF.
Multivariable stepwise logistic regression with backward elimination was subsequently used to determine the 
significant predictors of cardiac mortality and 1-year HHF among all the variables included in the univariable 
logistic regression. Variables that were significant with a P value of <0.05 were included in the final multivariable 
logistic models. Missing data were handled as case deletion without any imputation. Internal validity was assessed 
using bootstrapping techniques on the derivation cohort. External validity was assessed using the validation 
cohort. C-statistic (area under the curve) with 95%CI derived from Hosmer-Lemeshow test was used to assess the 
goodness of fit of the final multivariable logistic models. A model with a c-statistic of >0.800 was considered to 
have good fit. Misclassification rate derived from linear discriminant analysis was used to assess the discrimina-
tory power of the final multivariable logistic models. The final multivariable logistic models were used to develop 
nomograms for patient risk6.
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